Sweden Liquid Biopsy Market Size & Outlook, 2025-2033
The liquid biopsy market in Sweden is expected to reach a projected revenue of US$ 380.6 million by 2033. A compound annual growth rate of 11.7% is expected of Sweden liquid biopsy market from 2026 to 2033.
In terms of revenue, Sweden accounted for 1.1% of the global liquid biopsy market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany liquid biopsy market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 2,366.8 million by 2033.
Cancer is one of the leading causes of mortality in Sweden. According to Globocan 2020, 24,464 cancer deaths occurred in the country, and approximately 62,494 new cancer cases were diagnosed.
The Swedish government introduced the new EU Cancer Plan to reduce the burden of cancer. This plan emphasized improving the treatment of cancer. This was expected to improve the demand for effective diagnostics for use in cancer over the forecast period.
Continuous developments by companies operating in the market are contributing to the country’s growth. In December 2022, the Swedish market player Elypta announced plans to develop multicancer early detection test using glycosaminoglycan biomarkers.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Liquid Biopsy Market Outlook will help companies and investors design strategic landscapes.
Blood Sample Based was the largest segment with a revenue share of 81.19% in 2025.
Horizon Databook has segmented the Sweden liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2021 to 2033.
Cancer is one of the leading causes of mortality in Sweden. According to Globocan 2020, 24,464 cancer deaths occurred in the country, and approximately 62,494 new cancer cases were diagnosed.
The Swedish government introduced the new EU Cancer Plan to reduce the burden of cancer. This plan emphasized improving the treatment of cancer. This was expected to improve the demand for effective diagnostics for use in cancer over the forecast period.
Continuous developments by companies operating in the market are contributing to the country’s growth. In December 2022, the Swedish market player Elypta announced plans to develop multicancer early detection test using glycosaminoglycan biomarkers.
Sweden Liquid Biopsy Market Sample Type Outlook (Revenue, USD Million , 2021-2033)
Blood Sample Based
Others
Sweden Liquid Biopsy Market Biomarker Outlook (Revenue, USD Million , 2021-2033)
Circulating Nucleic Acids
CTC
Exosomes/Microvesicles
Circulating Proteins
Sweden Liquid Biopsy Market Technology Outlook (Revenue, USD Million , 2021-2033)
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
Sweden Liquid Biopsy Market Application Outlook (Revenue, USD Million , 2021-2033)
Cancer
Reproductive Health
Others
Sweden Liquid Biopsy Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals and Laboratories
Specialty Clinics
Academic and Research Centers
Others
Sweden Liquid Biopsy Market Clinical Application Outlook (Revenue, USD Million , 2021-2033)
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring
Others
Sweden Liquid Biopsy Market Product Outlook (Revenue, USD Million , 2021-2033)
Instruments
Consumables Kits and Reagents
Software and Services
Reasons to subscribe to Liquid Biopsy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Liquid Biopsy Market Outlook databook
Our clientele includes a mix of Liquid Biopsy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden Liquid Biopsy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Sweden Liquid Biopsy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.